Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
Panelists emphasized that for a patient with metastatic HER2-positive breast cancer and active brain metastases, selecting a treatment with proven intracranial activity is critical, while carefully considering prior therapy tolerability, radiation history, and the balance between treatment efficacy and patient convenience to optimize both disease control and quality of life.
The panel discussed a patient who is currently at her third line of therapy for metastatic HER2-positive breast cancer with brain metastases. Given her disease status, the preferred next step is a regimen known to be effective in this setting, especially for patients with active central nervous system (CNS) involvement. A commonly used treatment with demonstrated intracranial activity is often recommended, while the exact sequencing of newer agents remains under discussion. Treatment decisions must carefully consider how CNS metastases influence the choice of therapy and whether options are available that balance efficacy and patient convenience.
In discussing prior treatments, it’s important to explore why the patient discontinued a certain therapy that was not stopped due to disease progression. Reasons such as intolerable adverse effects, logistical challenges of frequent infusions, or inadequate management of symptoms like nausea and fatigue need to be addressed before choosing subsequent therapies. Radiation history also plays a role, as concerns about radiation necrosis after stereotactic radiosurgery may impact decisions regarding continuation or reintroduction of targeted agents. Timing between radiation and systemic therapy is critical in minimizing risks and maximizing benefits.
Finally, while the selected treatment regimen is appropriate for the patient’s current condition, it is important to acknowledge practical challenges, such as the need for regular institutional visits for infusions. Although some therapies provide impressive disease control, they can impose burdens on patients due to administration requirements. Anticipating future lines of therapy is essential, as patients with CNS disease often require multiple sequential treatments. Tailoring therapy to individual patient needs and preferences, while closely monitoring CNS disease, remains a key aspect of modern metastatic breast cancer care.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
